Compare GPOR & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GPOR | LGND |
|---|---|---|
| Founded | 1997 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.7B |
| IPO Year | 1998 | N/A |
| Metric | GPOR | LGND |
|---|---|---|
| Price | $200.13 | $208.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $228.13 | ★ $245.00 |
| AVG Volume (30 Days) | ★ 367.8K | 167.0K |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 245.92 | N/A |
| EPS | ★ 21.48 | N/A |
| Revenue | ★ $1,422,583,000.00 | N/A |
| Revenue This Year | $17.88 | $0.74 |
| Revenue Next Year | $6.71 | $19.04 |
| P/E Ratio | ★ $9.15 | $76.27 |
| Revenue Growth | ★ 48.47 | N/A |
| 52 Week Low | $153.41 | $93.58 |
| 52 Week High | $225.78 | $227.92 |
| Indicator | GPOR | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 49.93 | 56.23 |
| Support Level | $199.96 | $179.55 |
| Resistance Level | $215.65 | N/A |
| Average True Range (ATR) | 7.98 | 10.50 |
| MACD | -1.10 | 0.94 |
| Stochastic Oscillator | 37.07 | 60.65 |
Gulfport Energy Corp is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition, and production of natural gas, crude oil, and natural gas liquids, with assets predominantly located in the Appalachia and Anadarko basins in the United States. Its principal properties are located in eastern Ohio, targeting the Utica and Marcellus, and in central Oklahoma, targeting the SCOOP Woodford and Springer formations.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.